Compare Quest Diagnostics Inc (DGX) vs ThredUp Inc (TDUP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs ThredUp Inc — how do they compare? Quest Diagnostics Inc trades at $202.81 (market cap $22.80B), while ThredUp Inc trades at $6.62 (market cap $817.47M). The key difference: Quest Diagnostics Inc is far larger — about 27.9× ThredUp Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while ThredUp Inc pays none. Which is the better fit depends on your goals.
| DGX | TDUP | |
|---|---|---|
Market Cap | $22.80B | $817.47M |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $12.08 |
52-Week Low | $166.42 | $3.11 |
Enterprise Value | $28.82B | $820.21M |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
TDUP trades at $6.18, down 6.36% over 24 hours, with a mixed technical picture showing bullish moving averages but bearish oscillators. The company reported Q1 2026 revenue of $81.7 million, a 15% year-over-year increase, though net losses persist. Recent news highlights the launch of a peer-to-peer marketplace and AI-driven shopping features, signaling innovation efforts. Analyst sentiment remains positive with a consensus price target of $6.90 and 57% buy ratings.
The outlook hinges on TDUP's ability to leverage AI for cost reduction and growth in its resale platform, but risks include sustained profitability challenges and competitive pressures. With cash flow improving and debt levels manageable, the stock offers speculative upside if execution aligns with bullish analyst expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
